reports
Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to ...
Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company’s future financial per...
Tevogen to Align Long-Term Stock-Based Incentive Program With Company ...
Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that the current time- and individual performance-based long-term stock incentive program will be modified to align awards with defined company milestones including revenue. The updated program will be applicable to all employees, officers, directors and consultants who are eligible to participate in the Company’s long term incentives plan. Tevogen Founder and CEO, Dr. Ry...
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell ...
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025 Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare Conference WARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today reported significant scientific and operational milestones achieved in 2025 within its biotechnology operations, reflecting Tevogen’s continued execution toward a scalable, established, multi-program cell therapy development organization. In 2025, Tevogen advanced its proprietary ExacTcell™ platform, expa...
Tevogen CEO Donates Shares to Support Education for Underprivileged Ch...
Tevogen CEO Donates Shares to Support Education for Underprivileged Children WARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable contribution of 230,000 shares of Tevogen common stock to SRLC USA, a United Nations-recognized 501(c)(3) nonprofit organization dedicated to serving underserved communities. “Education is one of the most powerful long-term investments we can make in building healthier, more equitable societies,” said Dr. Saadi. “I’m pleased to su...
Tevogen CEO Donates Personal Shares to Support Local Fire Department
Tevogen CEO Donates Personal Shares to Support Local Fire Department WARREN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 50,000 shares of his personal holdings of Tevogen common stock to the Mt. Bethel Fire Company, supporting the organization’s mission to protect the Warren Township community. The donations reflect Dr. Saadi’s continued commitment to supporting first responders and the Warren Township community. “On behalf of the Mt. Bethel Fire Company, we’re since...
Tevogen CEO Supports Local Law Enforcement with Personal Contribution ...
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock WARREN, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 230,000 of his personal shares of common stock to the Warren Township Honorary Policemen’s Benevolent Association (P.B.A.) Local 235. The Warren Township Honorary P.B.A. Local 235 is a non-profit organization dedicated to supporting local schools, community events, and charitable causes. The organization...
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale Uni...
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine WARREN, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), is proud to recognize Curtis Patton, PhD, founding member of Tevogen’s Board of Directors and Professor Emeritus at Yale University, as he is honored in a new joint portrait commissioned by the Yale School of Medicine’s Program for Art in Public Spaces. The portrait celebrates the extraordinary, decades-long contrib...
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Bill...
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook WARREN, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that it has been named to the 2025 New Jersey Power List by NJBIZ, recognizing the most influential organizations shaping New Jersey’s economic and innovation landscape. NJBIZ highlighted Tevogen’s pioneering ExacTcell™ platform, its advancing pipeline in infectious diseases, oncology, and neurology, and the Company’s internally developed PredicTcell™ AI technology, designed...
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3...
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q WARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced the filing of its quarterly report on Form 10-Q for the quarter ended September 30, 2025, highlighting continued capital-efficient execution at a time when sustainability has become what the Company believes a defining challenge for the biotechnology industry. Tevogen reported a loss from operations calculated in accordance with U.S. GAAP of $5.7 million for the three months ended Sept...
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its ...
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk patientsTVGN 489 utilizes off-the-shelf, genetically unmodified allogeneic T cellsTVGN 489 is designed to address both acute COVID-19 infection and Long COVID WARREN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq...
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Eff...
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today issued a statement to provide clarity regarding its accumulated deficit reported under U.S. GAAP accounting standards in recent SEC filings. GAAP rules are designed for consistency and comparability across industries, but they can understate the value of high-growth biotechnology assets still under development. To offer investors a more comprehensive understanding of Tevogen’s financia...
Tevogen Senior Management Engages with Business and Community Leaders ...
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), in ongoing community, industry, and academic engagements, has continued to underscore its biopharma model centered on sustainability and patient affordability, highlighting the Company’s significant progress toward making precision medicine accessible to all. “The full potential of T cell therapies has yet to be explored. To matter, they must be accessible, off-the-shelf, well tolerated...
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Inter...
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of patient inquiries, Tevogen has established a dedicated communication channel for Long COVID updates at WARREN, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- WARREN, N.J., (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today issued an update regarding growing public interest in its investigational precision T cell ther...
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy...
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every time, dramatically raising the probability of success. WARREN, N.J., Sept. 25, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced significant progress in the development of its proprietary PredicTcell™ ...
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persisten...
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID WARREN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today highlights emerging scientific evidence linking persistent viral reservoirs to Long COVID, and emphasizes the potential of its investigational precision T cell therapy, TVGN 489, for the treatment of this debilitating condition which affects an estimated 20 million Americans and represents an area of unmet need. Peer-reviewed studies such as the ones published ...
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s ...
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary Robert F. Kennedy, Jr., and the Trump Administration for convening two Long COVID roundtables focused on patient experiences and research. Long COVID continues to affect millions of Americans; according to Yale Medicine, approximately 20 million adults in the U.S. are living wi...
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum ...
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025. The Startup Forum will feature insights from venture capital leaders and early-stage innovators on how they are scaling their companies with Databricks. Mehta ...
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product...
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today shared asset value and potential forecast for the Company’s pipeline product, TVGN 116, for liver cancer prevention with high-risk chronic Hepatitis B infections. The TVGN 116 cumulative 5-year top-line revenue forecast is es...
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Pro...
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for TVGN-489, an allogeneic precision T cell therapy and the first clinical-stage product from its proprietary ExacTcell™ platform. TVGN-489 is being developed for the treatment of SARS-CoV-2 infection in high-risk vulnerable patients and for Long-COVID in patie...
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipe...
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare disease eligible indications, the accessible market in the US could be as high as 40,000 patients.Focused on improved prognosis for patients with hematologic malignancies. WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today shared asset value and potential forecast for the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.